Revised Modified Response Evaluation Criteria in Solid Tumors for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1)
暂无分享,去创建一个
[1] Heber MacMahon,et al. Variability in mesothelioma tumor response classification. , 2006, AJR. American journal of roentgenology.
[2] A. Musk,et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Heber MacMahon,et al. Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniques. , 2004, Medical physics.
[4] Binsheng Zhao,et al. Assessment of Therapy Responses and Prediction of Survival in Malignant Pleural Mesothelioma Through Computer-Aided Volumetric Measurement on Computed Tomography Scans , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[5] Samuel G Armato,et al. Automated matching of temporally sequential CT sections. , 2004, Medical physics.
[6] S. Steinberg,et al. Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma. , 1998, The Journal of thoracic and cardiovascular surgery.
[7] M. Millward,et al. A Novel Prognostic Model for Malignant Mesothelioma Incorporating Quantitative FDG-PET Imaging with Clinical Parameters , 2010, Clinical Cancer Research.
[8] J Bogaerts,et al. Evaluation of lymph nodes with RECIST 1.1. , 2009, European journal of cancer.
[9] Samuel G Armato,et al. Characterization of mesothelioma and tissues present in contrast-enhanced thoracic CT scans. , 2011, Medical physics.
[10] L. Schwartz,et al. Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] D. Fielding,et al. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma , 2002, British Journal of Cancer.
[12] Ping Li,et al. Radiologic-pathologic correlation of mesothelioma tumor volume. , 2015, Lung cancer.
[13] Heber MacMahon,et al. Evaluation of semiautomated measurements of mesothelioma tumor thickness on CT scans. , 2005, Academic radiology.
[14] Arturo Chiti,et al. Early Response Evaluation in Malignant Pleural Mesothelioma by Positron Emission Tomography With [18F]Fluorodeoxyglucose , 2006 .
[15] A. Satterfield,et al. TREATMENT , 1924, California and western medicine.
[16] K. Nackaerts,et al. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. , 2017, The Lancet. Oncology.
[17] V. Rusch,et al. The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[18] Olivier Molinier,et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial , 2016, The Lancet.
[19] S. Armato,et al. Optimization of Response Classification Criteria for Patients with Malignant Pleural Mesothelioma , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[20] A. Miller,et al. Reporting results of cancer treatment , 1981, Cancer.
[21] Shin Matsuoka,et al. Epithelial malignant pleural mesothelioma after extrapleural pneumonectomy: stratification of survival with CT-derived tumor volume. , 2012, AJR. American journal of roentgenology.
[22] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[23] Robert C. Rintoul,et al. The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[24] H. Steinert,et al. Combined FDG-PET/CT in response evaluation of malignant pleural mesothelioma. , 2010, Lung cancer.
[25] Samuel G Armato,et al. Lung Volume Measurements as a Surrogate Marker for Patient Response in Malignant Pleural Mesothelioma , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[26] E. Scarpi,et al. FDG PET/CT Response Evaluation in Malignant Pleural Mesothelioma Patients Treated with Talc Pleurodesis and Chemotherapy , 2012, Journal of Cancer.
[27] M. Maio,et al. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study. , 2015, The Lancet. Respiratory medicine.
[28] T E Walsh,et al. Reporting results. , 1969, Archives of otolaryngology.
[29] Robert Ford,et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. , 2017, The Lancet. Oncology.
[30] Samuel G Armato,et al. Observer Variability in Mesothelioma Tumor Thickness Measurements: Defining Minimally Measurable Lesions , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[31] A. Hope,et al. Impact of tumour thickness on survival after radical radiation and surgery in malignant pleural mesothelioma , 2017, European Respiratory Journal.
[32] S. Armato,et al. Imaging in pleural mesothelioma: A review of the 12th International Conference of the International Mesothelioma Interest Group. , 2015, Lung cancer.
[33] Samuel G. Armato,et al. North American Multicenter Volumetric CT Study for Clinical Staging of Malignant Pleural Mesothelioma: Feasibility and Logistics of Setting Up a Quantitative Imaging Study , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[34] A. Fischman,et al. Fluorodeoxyglucose positron emission tomography and CT after talc pleurodesis. , 2004, Chest.
[35] M. Byrne,et al. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[36] Erich P Huang,et al. Metrology Standards for Quantitative Imaging Biomarkers. , 2015, Radiology.
[37] A. Santoro,et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. , 2017, The Lancet. Oncology.
[38] Roslyn J. Francis,et al. Early Prediction of Response to Chemotherapy and Survival in Malignant Pleural Mesothelioma Using a Novel Semiautomated 3-Dimensional Volume-Based Analysis of Serial 18F-FDG PET Scans , 2007, Journal of Nuclear Medicine.
[39] Samuel G Armato,et al. Modeling of mesothelioma growth demonstrates weaknesses of current response criteria. , 2006, Lung cancer.
[40] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[41] E. Eisenhauer,et al. Cancer clinical trial outcomes: any progress in tumour-size assessment? , 2009, European journal of cancer.
[42] M. Maio,et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. , 2013, The Lancet. Oncology.
[43] S. Armato,et al. Disease volumes as a marker for patient response in malignant pleural mesothelioma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.